COGT

The past six months have been marked by several significant events that have positively impacted Cogent Biosciences' stock price. In November 2025, Cogent reported positive top-line results from the Phase 3 PEAK trial of bezuclastinib in combination with sunitinib for GIST patients and completed public offerings generating approximately $546.8 million. In December 2025, the company submitted its NDA to the FDA for bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) and announced initial preclinical results for its JAK2 V617F inhibitor (CGT1145). In February 2026, Cogent provided a business update and reported strong financial results for 2025, highlighting the SUMMIT NDA submission and the initiation of the PEAK NDA under the FDA's RTOR program and BTD. In March 2026, the FDA accepted the NDA for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis. In April 2026, Cogent announced the submission of its NDA for bezuclastinib in GIST and positive Phase 3 PEAK trial data in GIST was selected for oral presentation at ASCO. In May 2026, the company reported recent business highlights and first-quarter 2026 financial results, indicating that multiple NDAs for bezuclastinib are under FDA review, with a PDUFA date of December 30, 2026, for NonAdvSM, and ended Q1 2026 with $866.4 million in cash, expected to fund operations into 2028.